Corporate Profile

The field of oncology is evolving rapidly and transforming how cancer is treated. We believe Incyte, rooted in rigorous science, is at the center of this transformation. Our pipeline includes innovative compounds in three major oncology areas: onco-inflammation, immuno-oncology and targeted therapies.

We believe our professional and financial resources, our experience and our prior success in bringing important new drugs to market put us in a strong position to make a difference in health care, improve the lives of patients and build sustainable value for our shareholders.


Recent News More >>
DateTitle 
December 09, 2014Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis
FIRST OF SEVERAL PHASE 3 TRIALS TO REPORT RESULTS INDIANAPOLIS, Dec. 9, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib met its primary endpoint of improved ACR20 response compared to placebo after 12 weeks of treatment. The study included patients with moderately-to-severely active rheumatoid arthritis (RA) who previously failed one or more tumor necrosis... 
Printer Friendly Version
December 04, 2014FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with Uncontrolled Polycythemia Vera
The first and only FDA-approved treatment for patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea PV is a rare blood cancer associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack1 Jakafi is the only treatment for patients with PV shown to provide consistent hematocrit con... 
Printer Friendly Version
December 02, 2014Multiple Data Presentations at the 2014 American Society of Hematology (ASH) Annual Meeting Showcase Incyte's Leadership in the Field of Myeloproliferative Neoplasms (MPNs)
New analyses of the RESPONSE trial provide additional insights into the efficacy of ruxolitinib in patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea Data from the COMFORT, JUMP, and EXPAND trials reinforce the efficacy and safety of ruxolitinib in patients with myelofibrosis (MF) Data from trials of the combination of ruxolitinib and other targeted agen... 
Printer Friendly Version

2013 Annual Report
2013 Annual Report Download Documentation

2013 10-K

Notice To Readers: Incyte's press releases, presentations and printed remarks are included on this Web site for historical purposes only. The information contained in these documents and webcasts should be considered accurate only as of the date of the relevant document or presentation. This information may change over time; therefore, visitors to this Web site should not assume that the information contained in these documents or presentations remains accurate at a later time. We do not have any current intention, and expressly disclaim any obligation, to supplement, update or revise any of the information in these documents or presentations.


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.